VTGN
VTGN
NASDAQ · Biotechnology

Vistagen Therapeutics Inc

$0.30
+0.02 (+8.79%)
As of Sep 28, 10:36 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.42M
Net Income
-78,081,490
Gross Margin
—
Profit Margin
-5,491.3%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 37.6% 37.6%
Operating Margin -5,683.7% -10,365.4% 26.4% 28.6%
Profit Margin -5,491.3% -10,050.9% 22.0% 24.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.42M 848.4K 9.03M 9.73M
Gross Profit — — 3.40M 3.66M
Operating Income -80,742,159 -87,942,529 2.39M 2.78M
Net Income -78,081,490 -80,993,442 1.99M 2.35M
Gross Margin — — 37.6% 37.6%
Operating Margin -5,683.7% -10,365.4% 26.4% 28.6%
Profit Margin -5,491.3% -10,050.9% 22.0% 24.2%
Rev Growth — -24.1% +1.4% +15.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 16.7K 0 10.09M 8.64M
Total Equity 6.20M — 16.52M 14.60M
D/E Ratio 0.00 — 0.61 0.59
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -80,589,926 -92,813,868 3.04M 3.38M
Free Cash Flow — — 1.40M 2.01M